New ECMO blood-thinning strategy with nafamostat
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a new way to manage blood-thinning medicine during ECMO (a machine that helps your heart and lungs). The goal is to see if using a drug called nafamostat in the ECMO circuit along with lower doses of a standard blood thinner can reduce side effects like bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are on ECMO (a machine that helps your heart and lungs) because of severe breathing failure.
- You do not have any medical reason that makes blood-thinning drugs unsafe for you.
- You have not had a stroke or are not suspected of having one.
- You do not have severe high blood pressure that is not well controlled.
- You are not pregnant or breastfeeding.
- You do not have hemophilia (a bleeding disorder).
- You are not allergic to heparin or nafamostat (blood-thinning medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a safe, backup ECMO machine for people with very weak hearts or complex blockages who need high-risk stenting. It helps keep your blood pumping if your heart struggles during the procedure.
This trial is for adults in the ICU who recently started ECMO (a heart-lung bypass machine). It tests whether a blood test called D-dimer can help predict bleeding risk, which might improve safety for people on ECMO.
This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.
This trial tests if bivalirudin is a safe and effective blood thinner for people on ECMO, a machine that helps your heart and lungs. You may be eligible if you need this therapy and have no past reactions to similar medicines.
This trial tests a medication called nafamostat mesilate to help control blood clotting problems caused by severe infections (sepsis). It may be an option for people with sepsis who are at risk of bleeding but do not have active bleeding.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
Hear when a new ECMO trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.